Global Spine Biologics Market 2016-2020

June 08, 2016
SKU:
IRTNTR9386
This market research report presents a detailed segmentation of the global spine biologics market by product (allograft, stem cells, BMP, DBM, and synthetic bone graft) and by geography (Americas, APAC, and EMEA). Leading vendors identified in the market are Medtronic, Johnson & Johnson, Stryker, NuVasive, Zimmer-Biomet, and SeaSpine.

Outlook of the spine biologics market

According to the market research analysts at Techanvio, the spine biologics market is anticipated to witness steady growth and will post a CAGR of more than 2% over the forecast period. The shift in preference to minimally invasive (MI) surgeries from open surgical methods have led to the augmented adoption of spine biologics in MI spine surgeries. Since conventional open surgeries can lead to various postoperative complications such as pain, partially collapsed lungs, blood clots, fatigue, muscle atrophy, and infections, the majority of medical facilities are opting for MI surgeries to repair the vertebrae and treat other spinal disorders. Moreover, anesthesia administered before surgeries can cause nausea, sore throat, and drowsiness. To reduce such complications, healthcare facilities are increasingly encouraging patients to undergo MI spinal procedures. As MI spinal surgeries offer advantages such as minimal blood loss, low infection rate, reduced pain in patients, and fast patient ambulation and retrieval, there’s been a rise in the popularity of MI lumbar fusion and facet fixation procedures. Additionally, MI spinal surgeries reduce hospital stays and lower the risk of complications as well as re-operations, resulting in significant cost-savings.

In this industry research report, the analysts have deduced factors such as the advances in technology and innovations in the healthcare industry to spur the growth prospects for this market in the coming years. These technological advances have led to the development of spinal implants that are compatible, durable, and offer physical strength. Moreover, the recent advances in genetic engineering and orthopedic medicine have allowed the replacement of traditional orthopedic biomaterials in spine surgeries. The newly developed spine biologics are selected based on certain parameters including thermal and electrical conductivity, diffusion, water absorption, biostability, and biocompatibility. The technological advancements in the medical sector and increasing focus on research are anticipated to drive the growth of this market until the end of 2020.

Product segmentation and analysis of the spine biologics market

  • Allograft
  • Stem cells
  • Bone morphogenetic protein (BMP)
  • Demineralized bone matrix (DBM)
  • Synthetic bone graft

During 2015, the synthetic bone graft segment dominated the market and accounted for more than 29% of the market share in terms of revenue. The synthetic bone graft material is composed of ceramic, calcium phosphates, and other synthetic materials such as tantalum, titanium, iron, polylactide, and silicate-based glasses in ceramics. These materials possess similar biochemical properties to that of cadaver bone, which is used as a bone graft substitute. Moreover, these synthetic materials allow the growth of the bone on the surface which gets resorbed by the body later. Synthetic bone substitutes are being increasingly used in orthopedic biomaterials as they are cost-effective, reduce the risk of disease transmission, and have improved outcomes. The increasing awareness among patients and the availability of advanced synthetic materials will result in significant growth of the synthetic bone grafts segment over the next four years. 

Geographical segmentation and analysis of the spine biologics market

  • Americas
  • APAC
  • EMEA

In terms of geography, the Americas dominated the global spine biologics market and is expected to reach more than USD 1 billion by 2020. The market in the Americas is growing steadily, however; the market is projected to witness rapid growth during the predicted period. The majority of medical facilities in the region prefer allografts to autologous bone grafts due to better patient outcome, fewer cases of donor site morbidity, and reduced surgical time. The increasing use of FDA approved innovative products is expected to drive this market’s growth in the Americas.

Competitive landscape and key vendors

The global spinal biologics market is highly dynamic and fragmented due to the presence of several large, medium, and small players. Although the key vendors hold dominant positions other factors such as innovation, design, and development of advanced products will change the competitive dynamics in the market. The competition among the vendors is expected to increase as they enter into partnerships or acquire distributors to increase their sales and expand their businesses worldwide.

 Key vendors in this market are -

  • Medtronic
  • Johnson & Johnson
  • Stryker
  • NuVasive
  • Zimmer-Biomet
  • SeaSpine

Other prominent vendors analyzed in this report are Alphatec Spine, AMEDICA, Anika Therapeutics, Arthrex, Baxter, Berkeley Advanced Biomaterial, Biomimetic Therapeutics, Globus Medical, Integra Life Sciences, ISTO Technologies, K2M, LDR, Orthofix International, RTI Surgical, and Xtant Medical.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global spinal biologics market?
  • What are the key market trends impacting the growth of the global spinal biologics market?
  • What are the challenges to market growth?
  • Who are the key vendors in global spinal biologics market?
  • What are the market opportunities and threats faced by the vendors in the global spinal biologics market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA. 
  • What are the key outcomes of the five forces analysis of global spinal biologics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

Spine biologics are used during spinal surgeries as lieu allografts and as support for bones in and around the spinal cord region. They can also be used to cure spinal injuries or degenerated discs and help to stimulate the process of bone growth and spinal fusion. Additionally, it offers various advantages, such as minimal postoperative pain, faster recovery, and shorter hospital stays, in addition to eliminating the need for harvesting bone matter from patients.

The report, global spine biologics market, is part of Technavio’s healthcare and life sciences research portfolio. This portfolio provides a comprehensive market analysis along with the market share, market sizing, and market segmentations covering areas such as cardiovascular and metabolic disorders, central nervous system, oncology, medical imaging, life science research tools, and vaccines. These market research reports provide a perspective on the various market opportunities and market threats along with the key trends that would influence the market growth during the forecast period. It presents insights into the changing competitive landscape and a detailed profiling and market analysis of the vendors. Also covered in the research are the key regions or countries that would have an impact on the market during the assessment years.